Treatment focuses on preventing additional ... This deficiency affects the GCase enzyme and increases a patient's risk of ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have ...

Conclusion: A patient with HIT developed severe skin necrosis after initiation of warfarin therapy. Warfarin is an integral component of heparin-induced thrombocytopenia (HIT) treatment.

The new 'living' guideline marks a major shift away from the traditional step-up approach, recommending early use of advanced therapies such as biologics and small molecules after 5-aminosalicylic ...

Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...

Teclison is a clinical stage oncology company advancing an immunotherapy treatment for solid tumors utilizing a three-pronged approach that: (1) induces tumor necrosis; (2) expands anti-tumor T cells ...

Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...